Rett syndrome (RTT) is a neurodevelopmental disorder predominantly occurring in females with an incidence of 1:10,000 births and caused by sporadic mutations in the MECP2 gene, which encodes methyl-CpG-binding protein-2, an epigenetic transcription factor that binds methylated DNA. The clinical hallmarks include a period of apparently normal early development followed by a plateau and then subsequent frank regression. Impaired visual and aural contact often lead to an initial diagnosis of autism. The characterization of experimental models based on the loss-of-function of the mouse Mecp2 gene revealed that subtle changes in the morphology and function of brain cells and synapses have profound consequences on network activities that underlie critical brain functions. Furthermore, these experimental models have been used for successful reversals of RTT-like symptoms by genetic, pharmacological and environmental manipulations, raising hope for novel therapeutic strategies to improve the quality of life of RTT individuals.
RettA. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien Med Wochenschr1966;116:723–6
2.
HagbergB, AicardiJ, DiasK, RamosO. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol1983;14:471–9
3.
LaurvickCL, de KlerkN, BowerC, ChristodoulouJ, RavineD, EllawayC, WilliamsonS, LeonardH. Rett syndrome in Australia: a review of the epidemiology. J Pediatr2006;148:347–52
4.
ChahrourM, ZoghbiHY. The story of Rett syndrome: from clinic to neurobiology. Neuron2007;56:422–37
5.
AmirRE, Van den VeyverIB, WanM, TranCQ, FranckeU, ZoghbiHY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet1999;23:185–8
6.
LewisJD, MeehanRR, HenzelWJ, Maurer-FogyI, JeppesenP, KleinF, BirdA. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell1992;69:905–14
7.
MeinsM, LehmannJ, GerresheimF, HerchenbachJ, HagedornM, HameisterK, EpplenJT. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet2005;42:e12
8.
FriezMJ, JonesJR, ClarksonK, LubsH, AbueloD, BierJA, PaiS, SimensenR, WilliamsC, GiampietroPF, SchwartzCE, StevensonRE. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics2006;118:e1687–95
9.
RamockiMB, TavyevYJ, PetersSU. The MECP2 duplication syndrome. Am J Med Genet A2010;152A:1079–88
10.
GirardM, CouvertP, CarrieA, TardieuM, ChellyJ, BeldjordC, BienvenuT. Parental origin of de novo MECP2 mutations in Rett syndrome. Eur J Hum Genet2001;9:231–6
11.
TrappeR, LacconeF, CobilanschiJ, MeinsM, HuppkeP, HanefeldF, EngelW. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet2001;68:1093–101
12.
KaufmannWE, MoserHW. Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex2000;10:981–91
13.
ArmstrongDD. Neuropathology of Rett syndrome. J Child Neurol2005;20:747–53
14.
JellingerK, ArmstrongD, ZoghbiHY, PercyAK. Neuropathology of Rett syndrome. Acta Neuropathol (Berl)1988;76:142–58
15.
ReissAL, FaruqueF, NaiduS, AbramsM, BeatyT, BryanRN, MoserH. Neuroanatomy of Rett syndrome: a volumetric imaging study. Ann Neurol1993;34:227–34
16.
BaumanML, KemperTL, ArinDM. Microscopic observations of the brain in Rett syndrome. Neuropediatrics1995;26:105–8
17.
BaumanML, KemperTL, ArinDM. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology1995;45:1581–6
18.
RonnettGV, LeopoldD, CaiX, HoffbuhrKC, MosesL, HoffmanEP, NaiduS. Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol2003;54:206–18
19.
ArmstrongD, DunnJK, AntalffyB, TrivediR. Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol1995;54:195–201
20.
ArmstrongDD, DunnK, AntalffyB. Decreased dendritic branching in frontal, motor and limbic cortex in Rett syndrome compared with trisomy 21. J Neuropathol Exp Neurol1998;57:1013–7
21.
KaufmannWE, NaiduS, BuddenS. Abnormal expression of microtubule-associated protein 2 (MAP-2) in neocortex in Rett syndrome. Neuropediatrics1995;26:109–13
22.
KaufmannWE, MacDonaldSM, AltamuraCR. Dendritic cytoskeletal protein expression in mental retardation: an immunohistochemical study of the neocortex in Rett syndrome. Cereb Cortex2000;10:992–1004
23.
BlueME, NaiduS, JohnstonMV. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol1999;156:345–52
24.
BlueME, NaiduS, JohnstonMV. Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol1999;45:541–5
25.
PanJW, LaneJB, HetheringtonH, PercyAK. Rett syndrome: 1H spectroscopic imaging at 4.1 Tesla. J Child Neurol1999;14:524–8
26.
BelichenkoPV, OldforsA, HagbergB, DahlstromA. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport1994;5:1509–13
27.
ChapleauCA, CalfaGD, LaneMC, AlbertsonAJ, LarimoreJL, KudoS, ArmstrongDL, PercyAK, Pozzo-MillerL. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol Dis2009;35:219–33
28.
KaufmannWE, WorleyPF, TaylorCV, BremerM, IsaksonPC. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev1997;19:25–34
29.
PurpuraDP. Dendritic spine “dysgenesis” and mental retardation. Science1974;186:1126–8
30.
FialaJC, SpacekJ, HarrisKM. Dendritic spine pathology: cause or consequence of neurological disorders?Brain Res Brain Res Rev2002;39:29–54
31.
ChapleauCA, LarimoreJL, TheibertA, Pozzo-MillerL. Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J Neurodev Disord2009;1:185–96
32.
HendrichB, BirdA. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol1998;18:6538–47
33.
NanX, MeehanRR, BirdA. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res1993;21:4886–92
34.
NanX, CampoyFJ, BirdA. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell1997;88:471–81
35.
NanX, CrossS, BirdA. Gene silencing by methyl-CpG-binding proteins. Novartis Found Symp1998;214:6–16
36.
ChahrourM, JungSY, ShawC, ZhouX, WongST, QinJ, ZoghbiHY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science2008;320:1224–9
37.
YoungJI, HongEP, CastleJC, Crespo-BarretoJ, BowmanAB, RoseMF, KangD, RichmanR, JohnsonJM, BergetS, ZoghbiHY. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci USA2005;102:17551–8
38.
ShahbazianM, YoungJ, Yuva-PaylorL, SpencerC, AntalffyB, NoebelsJ, ArmstrongD, PaylorR, ZoghbiH. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron2002;35:243–54
39.
ReichwaldK, ThiesenJ, WieheT, WeitzelJ, PoustkaWA, RosenthalA, PlatzerM, StratlingWH, KioschisP. Comparative sequence analysis of the MECP2-locus in human and mouse reveals new transcribed regions. Mamm Genome2000;11:182–90
40.
KriaucionisS, BirdA. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res2004;32:1818–23
41.
MnatzakanianGN, LohiH, MunteanuI, AlfredSE, YamadaT, MacLeodPJ, JonesJR, SchererSW, SchanenNC, FriezMJ, VincentJB, MinassianBA. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet2004;36:339–41
42.
JungBP, JugloffDG, ZhangG, LoganR, BrownS, EubanksJH. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J Neurobiol2003;55:86–96
43.
KishiN, MacklisJD. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci2004;27:306–21
44.
DragichJM, KimYH, ArnoldAP, SchanenNC. Differential distribution of the MeCP2 splice variants in the postnatal mouse brain. J Comp Neurol2007;501:526–42
45.
BebbingtonA, AndersonA, RavineD, FyfeS, PinedaM, de KlerkN, Ben-ZeevB, YatawaraN, PercyA, KaufmannWE, LeonardH. Investigating genotype–phenotype relationships in Rett syndrome using an international data set. Neurology2008;70:868–75
46.
NeulJL, FangP, BarrishJ, LaneJ, CaegEB, SmithEO, ZoghbiH, PercyA, GlazeDG. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology2008;70:1313–21
47.
GlazeDG, PercyAK, SkinnerS, MotilKJ, NeulJL, BarrishJO, LaneJB, GeertsSP, AnneseF, GrahamJ, McNairL, LeeHS. Epilepsy and the natural history of Rett syndrome. Neurology2010;74:909–12
48.
PercyAK, LaneJB, ChildersJ, SkinnerS, AnneseF, BarrishJ, CaegE, GlazeDG, MacLeodP. Rett syndrome: North American database. J Child Neurol2007;22:1338–41
49.
ArcherHL, WhatleySD, EvansJC, RavineD, HuppkeP, KerrA, BunyanD, KerrB, SweeneyE, DaviesSJ, ReardonW, HornJ, MacDermotKD, SmithRA, MageeA, DonaldsonA, CrowY, HermonG, MiedzybrodzkaZ, CooperDN, LazarouL, ButlerR, SampsonJ, PilzDT, LacconeF, ClarkeAJ. Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet2006;43:451–6
50.
CollinsAL, LevensonJM, VilaythongAP, RichmanR, ArmstrongDL, NoebelsJL, David SweattJ, ZoghbiHY. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet2004;13:2679–89
51.
KankirawatanaP, LeonardH, EllawayC, ScurlockJ, MansourA, MakrisCM, DureLST, FriezM, LaneJ, Kiraly-BorriC, FabianV, DavisM, JacksonJ, ChristodoulouJ, KaufmannWE, RavineD, PercyAK. Early progressive encephalopathy in boys and MECP2 mutations. Neurology2006;67:164–6
52.
del GaudioD, FangP, ScagliaF, WardPA, CraigenWJ, GlazeDG, NeulJL, PatelA, LeeJA, IronsM, BerrySA, PursleyAA, GrebeTA, FreedenbergD, MartinRA, HsichGE, KheraJR, FriedmanNR, ZoghbiHY, EngCM, LupskiJR, BeaudetAL, CheungSW, RoaBB. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med2006;8:784–92
53.
TateP, SkarnesW, BirdA. The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse. Nat Genet1996;12:205–8
54.
SauerB. Inducible gene targeting in mice using the Cre/lox system. Methods1998;14:381–92
55.
SchwenkF, BaronU, RajewskyK. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res1995;23:5080–1
56.
GuyJ, HendrichB, HolmesM, MartinJE, BirdA. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet2001;27:322–6
57.
BraunschweigD, SimcoxT, SamacoRC, LaSalleJM. X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2−/+ mouse brain. Hum Mol Genet2004;13:1275–86
58.
TroncheF, KellendonkC, KretzO, GassP, AnlagK, OrbanPC, BockR, KleinR, SchutzG. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet1999;23:99–103
59.
SamacoRC, FryerJD, RenJ, FyffeS, ChaoHT, SunY, GreerJJ, ZoghbiHY, NeulJL. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet2008;17:1718–27
60.
PelkaGJ, WatsonCM, RadziewicT, HaywardM, LahootiH, ChristodoulouJ, TamPP. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain2006;129(Pt 4):887–98
61.
ChenRZ, AkbarianS, TudorM, JaenischR. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet2001;27:327–31
62.
LuikenhuisS, GiacomettiE, BeardCF, JaenischR. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA2004;101:6033–8
63.
MinichielloL, KorteM, WolferD, KuhnR, UnsickerK, CestariV, Rossi-ArnaudC, LippHP, BonhoefferT, KleinR. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron1999;24:401–14
64.
BalthasarN, DalgaardLT, LeeCE, YuJ, FunahashiH, WilliamsT, FerreiraM, TangV, McGovernRA, KennyCD, ChristiansenLM, EdelsteinE, ChoiB, BossO, AschkenasiC, ZhangCY, MountjoyK, KishiT, ElmquistJK, LowellBB. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell2005;123:493–505
65.
FyffeSL, NeulJL, SamacoRC, ChaoHT, Ben-ShacharS, MorettiP, McGillBE, GouldingEH, SullivanE, TecottLH, ZoghbiHY. Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress. Neuron2008;59:947–58
66.
LindebergJ, UsoskinD, BengtssonH, GustafssonA, KylbergA, SoderstromS, EbendalT. Transgenic expression of Cre recombinase from the tyrosine hydroxylase locus. Genesis2004;40:67–73
67.
SamacoRC, Mandel-BrehmC, ChaoHT, WardCS, Fyffe-MaricichSL, RenJ, HylandK, ThallerC, MaricichSM, HumphreysP, GreerJJ, PercyA, GlazeDG, ZoghbiHY, NeulJL. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci USA2009;106:21966–71
68.
ScottMM, WylieCJ, LerchJK, MurphyR, LoburK, HerlitzeS, JiangW, ConlonRA, StrowbridgeBW, DenerisES. A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci USA2005;102:16472–7
69.
AdachiM, AutryAE, CovingtonHEIII, MonteggiaLM. MeCP2-mediated transcription repression in the basolateral amygdala may underlie heightened anxiety in a mouse model of Rett syndrome. J Neurosci2009;29:4218–27
70.
HamiltonAJ, BaulcombeDC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science1999;286:950–2
71.
ElbashirSM, HarborthJ, LendeckelW, YalcinA, WeberK, TuschlT. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature2001;411:494–8
72.
JinJ, BaoX, WangH, PanH, ZhangY, WuX. RNAi-induced down-regulation of Mecp2 expression in the rat brain. Int J Dev Neurosci2008;26:457–65
73.
WoodL, GrayNW, ZhouZ, GreenbergME, ShepherdGM. Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. J Neurosci2009;29:12440–8
74.
Lawson-YuenA, LiuD, HanL, JiangZI, TsaiGE, BasuAC, PickerJ, FengJ, CoyleJT. Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. Brain Res2007;1180:1–6
75.
JentarraGM, OlfersSL, RiceSG, SrivastavaN, HomanicsGE, BlueM, NaiduS, NarayananV. Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation. BMC Neurosci2010;11:19
76.
HottaA, CheungAY, FarraN, VijayaragavanK, SeguinCA, DraperJS, PasceriP, MaksakovaIA, MagerDL, RossantJ, BhatiaM, EllisJ. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods2009;6:370–6
77.
RicceriL, De FilippisB, LaviolaG. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav Pharmacol2008;19:501–17
78.
TaoJ, WuH, SunYE. Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons. Int Rev Neurobiol2009;89:147–60
79.
YoungJI, ZoghbiHY. X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome. Am J Hum Genet2004;74:511–20
80.
MetcalfBM, MullaneyBC, JohnstonMV, BlueME. Temporal shift in methyl-CpG binding protein 2 expression in a mouse model of Rett syndrome. Neuroscience2006;139:1449–60
81.
StearnsNA, SchaevitzLR, BowlingH, NagN, BergerUV, Berger-SweeneyJ. Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neuroscience2007;146:907–21
82.
BissonnetteJM, KnoppSJ. Effect of inspired oxygen on periodic breathing in methy-CpG-binding protein 2 (Mecp2) deficient mice. J Appl Physiol2008;104:198–204
83.
JugloffDG, VandammeK, LoganR, VisanjiNP, BrotchieJM, EubanksJH. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet2008;17:1386–96
84.
KondoM, GrayLJ, PelkaGJ, ChristodoulouJ, TamPP, HannanAJ. Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome – Mecp2 gene dosage effects and BDNF expression. Eur J Neurosci2008;27:3342–50
85.
WardBC, AgarwalS, WangK, Berger-SweeneyJ, KolodnyNH. Longitudinal brain MRI study in a mouse model of Rett Syndrome and the effects of choline. Neurobiol Dis2008;31:110–19
86.
BelichenkoNP, BelichenkoPV, MobleyWC. Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol Dis2009;34:71–7
87.
D'CruzJA, WuC, ZahidT, El-HayekY, ZhangL, EubanksJH. Alterations of cortical and hippocampal EEG activity in MeCP2-deficient mice. Neurobiol Dis2010;38:8–16
88.
LonettiG, AngelucciA, MorandoL, BoggioEM, GiustettoM, PizzorussoT. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol Psychiatry2010;67:657–65
89.
RouxJC, PanayotisN, DuraE, VillardL. Progressive noradrenergic deficits in the locus coeruleus of Mecp2 deficient mice. J Neurosci Res2010;88:1500–9
90.
IsodaK, MorimotoM, MatsuiF, HasegawaT, TozawaT, MoriokaS, ChiyonobuT, NishimuraA, YoshimotoK, HosoiH. Postnatal changes in serotonergic innervation to the hippocampus of methyl-CpG-binding protein 2-null mice. Neuroscience2010;165:1254–60
91.
HagbergB, GoutieresF, HanefeldF, RettA, WilsonJ. Rett syndrome: criteria for inclusion and exclusion. Brain Dev1985;7:372–3
92.
MorettiP, LevensonJM, BattagliaF, AtkinsonR, TeagueR, AntalffyB, ArmstrongD, ArancioO, SweattJD, ZoghbiHY. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J Neurosci2006;26:319–27
93.
GemelliT, BertonO, NelsonED, PerrottiLI, JaenischR, MonteggiaLM. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry2006;59:468–76
KlauckSM, LindsayS, BeyerKS, SplittM, BurnJ, PoustkaA. A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. Am J Hum Genet2002;70:1034–7
96.
NanX, HouJ, MacleanA, NasirJ, LafuenteMJ, ShuX, KriaucionisS, BirdA. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc Natl Acad Sci USA2007;104:2709–14
97.
BallasN, LioyDT, GrunseichC, MandelG. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci2009;12:311–7
FukudaT, ItohM, IchikawaT, WashiyamaK, GotoY. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol2005;64:537–44
100.
SmrtRD, Eaves-EgenesJ, BarkhoBZ, SantistevanNJ, ZhaoC, AimoneJB, GageFH, ZhaoX. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis2007;27:77–89
101.
TropeaD, GiacomettiE, WilsonNR, BeardC, McCurryC, FuDD, FlanneryR, JaenischR, SurM. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA2009;106:2029–34
102.
BelichenkoPV, WrightEE, BelichenkoNP, MasliahE, LiHH, MobleyWC, FranckeU. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol2009;514:240–58
103.
DeganoAL, PasterkampRJ, RonnettGV. MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function. Mol Cell Neurosci2009;42:243–54
ZhangZW, ZakJD, LiuH. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J Neurophysiol2010;103:2470–81
106.
DaniVS, ChangQ, MaffeiA, TurrigianoGG, JaenischR, NelsonSB. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci USA2005;102:12560–5
107.
DengV, MatagneV, BanineF, FrerkingM, OhligerP, BuddenS, PevsnerJ, DissenGA, ShermanLS, OjedaSR. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet2007;16:640–50
108.
ZhangL, HeJ, JugloffDG, EubanksJH. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus2008;18:294–309
GambinoF, KhelfaouiM, PoulainB, BienvenuT, ChellyJ, HumeauY. Synaptic maturation at cortical projections to the lateral amygdala in a mouse model of Rett syndrome. PLoS One2010;5:e11399
111.
TanejaP, OgierM, Brooks-HarrisG, SchmidDA, KatzDM, NelsonSB. Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J Neurosci2009;29:12187–95
112.
DaniVS, NelsonSB. Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. J Neurosci2009;29:11263–70
113.
ChangQ, KhareG, DaniV, NelsonS, JaenischR. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron2006;49:341–8
114.
MedrihanL, TantalakiE, AramuniG, SargsyanV, DudanovaI, MisslerM, ZhangW. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol2008;99:112–21
115.
OgierM, WangH, HongE, WangQ, GreenbergME, KatzDM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci2007;27:10912–7
116.
ZuckerRS. Short-term synaptic plasticity. Ann Rev Neurosci1989;12:13–31
117.
AsakaY, JugloffDG, ZhangL, EubanksJH, FitzsimondsRM. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis2006;21:217–27
118.
BoggioEM, LonettiG, PizzorussoT, GiustettoM. Synaptic determinants of Rett syndrome. Frontiers in Synaptic Neuroscience2010;2:28
119.
MalenkaRC, BearMF. LTP and LTD: an embarrassment of riches. Neuron2004;44:5–21
120.
GuyJ, GanJ, SelfridgeJ, CobbS, BirdA. Reversal of neurological defects in a mouse model of Rett syndrome. Science2007;315:1143–7
121.
MaezawaI, SwanbergS, HarveyD, LaSalleJM, JinLW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci2009;29:5051–61
KudoS, NomuraY, SegawaM, FujitaN, NakaoM, DragichJ, SchanenC, TamuraM. Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems. Brain Dev2001;23(Suppl 1):S165–73
128.
KudoS, NomuraY, SegawaM, FujitaN, NakaoM, SchanenC, TamuraM. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet2003;40:487–93
129.
GhoshRP, Horowitz-SchererRA, NikitinaT, GieraschLM, WoodcockCL. Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions. J Biol Chem2008;283:20523–34
130.
HoKL, McNaeIW, SchmiedebergL, KloseRJ, BirdAP, WalkinshawMD. MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell2008;29:525–31
RosenmundC, StevensCF. Definition of the readily releasable pool of vesicles at hippocampal synapses. Neuron1996;16:1197–207
133.
HesslerNA, ShirkeAM, MalinowR. The probability of transmitter release at a mammalian central synapse. Nature1993;366:569–72
134.
LiuH, DeanC, ArthurCP, DongM, ChapmanER. Autapses and networks of hippocampal neurons exhibit distinct synaptic transmission phenotypes in the absence of synaptotagmin I. J Neurosci2009;29:7395–403
135.
GiacomettiE, LuikenhuisS, BeardC, JaenischR. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA2007;104:1931–6
136.
MaezawaI, JinLW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci2010;30:5346–56
FernandezF, MorishitaW, ZunigaE, NguyenJ, BlankM, MalenkaRC, GarnerCC. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci2007;10:411–3
139.
RuedaN, FlorezJ, Martinez-CueC. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett2008;433:22–7
140.
CostaRM, FederovNB, KoganJH, MurphyGG, SternJ, OhnoM, KucherlapatiR, JacksT, SilvaAJ. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature2002;415:526–30
141.
LiW, CuiY, KushnerSA, BrownRA, JentschJD, FranklandPW, CannonTD, SilvaAJ. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol2005;15:1961–7
142.
EhningerD, HanS, ShilyanskyC, ZhouY, LiW, KwiatkowskiDJ, RameshV, SilvaAJ. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med2008;14:843–8
143.
MeikleL, PollizziK, EgnorA, KramvisI, LaneH, SahinM, KwiatkowskiDJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci2008;28:5422–32
144.
ZengLH, XuL, GutmannDH, WongM. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol2008;63:444–53
145.
BourtchouladzeR, LidgeR, CatapanoR, StanleyJ, GossweilerS, RomashkoD, ScottR, TullyT. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA2003;100:10518–22
146.
AlarconJM, MalleretG, TouzaniK, VronskayaS, IshiiS, KandelER, BarcoA. Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron2004;42:947–59
147.
DolenG, OsterweilE, RaoBS, SmithGB, AuerbachBD, ChattarjiS, BearMF. Correction of fragile X syndrome in mice. Neuron2007;56:955–62
148.
van WoerdenGM, HarrisKD, HojjatiMR, GustinRM, QiuS, de Avila FreireR, JiangYH, ElgersmaY, WeeberEJ. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci2007;10:280–2
149.
BelichenkoPV, DahlstromA. Studies on the 3-dimensional architecture of dendritic spines and varicosities in human cortex by confocal laser scanning microscopy and Lucifer yellow microinjections. J Neurosci Methods1995;57:55–61
150.
ArmstrongDD. Neuropathology of Rett syndrome. Ment Retard Dev Disabil Res Rev2002;8:72–6
151.
CobbS, GuyJ, BirdA. Reversibility of functional deficits in experimental models of Rett syndrome. Biochem Soc Trans2010;38:498–506
152.
Alvarez-SaavedraM, SaezMA, KangD, ZoghbiHY, YoungJI. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum Mol Genet2007;16:2315–25
153.
ChenWG, ChangQ, LinY, MeissnerA, WestAE, GriffithEC, JaenischR, GreenbergME. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science2003;302:885–9
154.
MartinowichK, HattoriD, WuH, FouseS, HeF, HuY, FanG, SunYE. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science2003;302:890–3
155.
BlackIB. Trophic regulation of synaptic plasticity. J Neurobiol1999;41:108–18
156.
PooMM. Neurotrophins as synaptic modulators. Nat Rev Neurosci2001;2:24–32
157.
TylerWJ, AlonsoM, BramhamCR, Pozzo-MillerLD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem2002;9:224–37
158.
LuB. BDNF and activity-dependent synaptic modulation. Learn Mem2003;10:86–98
159.
RiosM, FanG, FeketeC, KellyJ, BatesB, KuehnR, LechanRM, JaenischR. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol2001;15:1748–57
160.
LauterbornJC, LynchG, VanderklishP, AraiA, GallCM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci2000;20:8–21
161.
LynchG, GallCM. Ampakines and the threefold path to cognitive enhancement. Trends Neurosci2006;29:554–62
162.
WangH, ChanSA, OgierM, HellardD, WangQ, SmithC, KatzDM. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J Neurosci2006;26:10911–5
163.
ZhengWH, QuirionR. Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J Neurochem2004;89:844–52
164.
RouxJC, DuraE, MonclaA, ManciniJ, VillardL. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci2007;25:1915–22
165.
NagN, Berger-SweeneyJE. Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome. Neurobiol Dis2007;26:473–80
166.
NagN, MellottTJ, Berger-SweeneyJE. Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome. Brain Res2008;1237:101–9
167.
WardBC, KolodnyNH, NagN, Berger-SweeneyJE. Neurochemical changes in a mouse model of Rett syndrome: changes over time and in response to perinatal choline nutritional supplementation. J Neurochem2009;108:361–71
168.
van PraagH, KempermannG, GageFH. Neural consequences of environmental enrichment. Nat Rev Neurosci2000;1:191–8
169.
NithianantharajahJ, HannanAJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci2006;7:697–709
